Gerald W. McLaughlin

This profile gathers the share dealings of Gerald W. McLaughlin across 4 companies, led by Neos Therapeutics, Inc., Nupathe Inc. and Skye Bioscience, Inc. Over a trading history stretching from 7 January 2013 to 8 April 2021, the count stands at 13 filings.

No open-market sale appears; the market trades are 2 purchases worth €45k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 7 share grants.

Most recently, on 12 April 2021, the filings show a share grant in Aytu Biopharma, Inc. The most recent open-market purchase was published on 10 December 2018, 2,874 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.